These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 269705)
1. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case. Coates AS; Peters M Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705 [TBL] [Abstract][Full Text] [Related]
2. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108 [TBL] [Abstract][Full Text] [Related]
3. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Mastrangelo MJ; Bellet RE; Berkelhammer J; Clark WH Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548 [TBL] [Abstract][Full Text] [Related]
5. Surgical treatment of malignant melanoma. Rosenberg SA Cancer Treat Rep; 1976 Feb; 60(2):159-63. PubMed ID: 769968 [TBL] [Abstract][Full Text] [Related]
6. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival. McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909 [TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970 [TBL] [Abstract][Full Text] [Related]
8. BCG immunotherapy in patients with malignant melanoma. Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125 [TBL] [Abstract][Full Text] [Related]
9. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy. de la Monte SM; Hutchins GM Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854 [TBL] [Abstract][Full Text] [Related]
10. Results of adjuvant BCG immunotherapy in malignant melanoma. Wätzig V; Knopf B Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442 [TBL] [Abstract][Full Text] [Related]
11. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative. Lokich JJ; Garnick MB; Legg M Oncology; 1979; 36(5):236-41. PubMed ID: 481845 [TBL] [Abstract][Full Text] [Related]